Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.46 |
| ▸ | CES1 | P23141 | 8/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19163900 | 0.97 | FAAH (0.48) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL13661862 | 0.97 | FAAH (0.48) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL16722811 | 0.97 | FAAH (0.48) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL16640758 | 0.97 | FAAH (0.48) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL12247043 | 0.97 | FAAH (0.48) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL18751671 | 0.97 | FAAH (0.48) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL5021516 | 0.93 | FAAH (0.40) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL7256359 | 0.89 | LMNA (0.58) | KMT2AMEN1HSD17B10LMNAALDH1A1 | |
| SCHEMBL3631010 | 0.89 | FAAH (0.62) | FAAHCES1CES2KMT2AMEN1 | |
| SCHEMBL2529981 | 0.89 | GPR84 (0.46) | FAAHCES1CES2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209149-A1 | BIO-BASED POLYAMIDE ELASTOMER AND PREPARATION METHOD THEREFOR | CATHAY BIOTECH INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20210252159-A1 | CONJUGATES OF CARTILAGE-HOMING PEPTIDES | FRED HUTCHINSON CANCER CENTER | 2021-08-19 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170254798-A1 | METHOD FOR SCREENING DRUG-SACCHARIDE CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170248580-A1 | METHOD FOR SCREENING DRUG-SACCHARIDE CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170119907-A1 | Targeted Therapeutics | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | FAAH 2211/4885CES1 543/4885CES2 363/4885 |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | FAAH 4547/4885CES1 871/4885CES2 974/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | FAAH 4668/4885CES1 854/4885CES2 876/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | FAAH 2231/4885CES1 609/4885CES2 406/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | FAAH 4675/4885CES1 1190/4885CES2 1207/4885 |
| US-20210252159-A1 | CONJUGATES OF CARTILAGE-HOMING PEPTIDES | CD44, MATR3, CCL2 | FAAH 3675/4885CES1 2239/4885CES2 3077/4885 |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | FAAH 2626/4885CES1 1697/4885CES2 2734/4885 |
| US-20170119907-A1 | Targeted Therapeutics | ANXA3, ANXA5, ANXA6 | FAAH 3179/4885CES1 3839/4885CES2 2041/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | FAAH 2626/4885CES1 1697/4885CES2 2734/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | FAAH 2626/4885CES1 1697/4885CES2 2734/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | FAAH 2626/4885CES1 1697/4885CES2 2734/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | FAAH 4668/4885CES1 854/4885CES2 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.